Approximately 45% of Chinese and Japanese individuals have the inactive ALDH2 genotypes (ALDH2*2/ *2 and ALDH2*1/*2); acute inhalation toxicity of acetaldehyde has not been evaluated in these populations. We compared the toxicity between wild-type (Aldh2+/+) and Aldh2-inactive transgenic (Aldh2−/−) mice by using the paired acute inhalation test modified from the acute toxic class method (OECD TG433). Blood acetaldehyde level was measured 4 hr after the inhalation. A pair of Aldh2+/+ and Aldh2−/− mice was put into a chamber and was exposed to 5000 ppm of acetaldehyde. At the start of the inhalation, the mice exhibited hypoactivity and closing of the eyes. Subsequently, symptoms such as crouching, bradypnea, and piloerection were observed. Flushing was observed only in the Aldh2+/+ mice. Symptoms such as tears, straggling gait, prone position, pale skin, abnormal deep respiration, dyspnea, and one case of death were observed only in the Aldh2−/− mice. The symptoms did not change 1 hr after inhalation in the Aldh2+/+ mice. In contrast, in the Aldh2−/− mice, the symptoms became more severe until the end of the inhalation. The blood acetaldehyde level in the Aldh2−/− mice was approximately twice that in the Aldh2+/+ mice 4 hr after inhalation. The Aldh2−/− mice evidently showed more severe toxicity as compared with the Aldh2+/+ mice due to acute inhalation of acetaldehyde at a concentration of 5000 ppm. Acetaldehyde toxicity in Aldh2+/+ and Aldh2−/− mice was estimated and classified one class different. Based on this study, acetaldehyde inhalations were inferred to pose a higher risk to ALDH2-inactive human individuals.
INTRODUCTION
Acetaldehyde is widely produced as an intermediary product of alcohol, acetic acid, certain esters, and a number of other chemicals in ethylene and alcohol fermentation plants; it is also present in tobacco smoke (IPCS, 1995) . Acetaldehyde is rapidly metabolized to acetic acid by aldehyde dehydrogenase (ALDH; Brein and Loomis, 1983) . ALDH is better known as one of the enzymes involved in the ethanol metabolizing process. Ingested ethanol is oxidized by cytosolic class I alcohol dehydrogenase 2 (ADH2) to acetaldehyde, which is further oxidized by mitochondrial aldehyde dehydrogenase 2 (ALDH2) to produce acetate. More than 95% of ethanol-derived acetaldehyde is oxidized by the liver mitochondrial ALDH (ALDH2) (Eriksson, 1977) .
A high sensitivity (i.e., facial flushing, increase in pulse rate, elevation of blood acetaldehyde level, low alcohol tolerance) caused by ethanol-derived acetaldehyde is more commonly observed in Asians than Caucasians (Wolff, 1972) . This sensitivity in Asians is associated with a severe deficiency in ALDH2 activity, which is caused by a point mutation involving a G→A transition at nt 1510, resulting in a Glu→Lys substitution in the protein at position 487 (Yoshida et al., 1984) . ALDH2 is an allosteric tetrameric enzyme, and the ALDH2 tetramer containing inactivated monomers that are derived from the G→A transition at nt 1510 do not show an enzymatic activity (Weiner et al., 2001) . Thus, both heterozygotes and homozygotes of this ALDH2 genotype appear as inactive ALDH2 phenotype.
There are more than 1.3 × 10 9 (million) Chinese and Japanese in the world. Most of the ALDH2-inactive individuals are distributed in these populations, and it is estimated that approximately 45% of the people in these populations are ALDH2-inactive (Dandre et al., 1995; Goddele, 1992; Matsuo et al., 2001; Mizoi et al., 1994; Novoradovsky et al., 1995) . Many studies have been conducted to investigate the internal exposure to acetaldehyde due to alcohol consumption. Using pharmacokinetic-Monte Carlo simulation, Ginsberg et al. (2002) carried out the population risk assessment of internal acetaldehyde exposure due to ethanol consumption. Exposure to acetaldehyde is not only due to ethanol consumption but also due to the use of acetaldehyde in industrial and household materials. ALDH2-inactive individuals were estimated to be at a higher risk of toxicity due to a higher internal exposure to acetaldehyde. However, no data or evidence is available on the accidental inhalation of acetaldehyde in ALDH2-inactive individuals because acetaldehyde is globally produced only by a limited number of companies. In Japan, acetaldehyde is produced by three companies, and the total acetaldehyde production in 2003 amounted to 362,000 tonnes (The Chemical Daily, 2005) . Acetaldehyde is a commonly used chemical, and the population of ALDH2-inactive individuals is large. It is important to evaluate whether acetaldehyde itself is the cause of higher toxicity in ALDH2-inactive individuals.
A few studies are available on acetaldehyde inhalation toxicity. The concentrations of acetaldehyde used in a human study were below the detection limit (1−3.4 mg/m 3 ) or as low as in occupational exposure (IPCS, 1995) . The mouse Aldh2 gene encodes a protein with 519 amino acid residues and shares 95.8% identity with the human ALDH2 (Chang and Yoshida, 1994) . Thus, we generated Aldh2 transgenic mice that had null ALDH2 activity (Kitagawa et al., 2000) in order to directly elucidate the acetaldehyde inhalation toxicity differences between ALDH2-inactive individuals and wild-type-ALDH2 individuals. Iwanoff (1911) first reported about acetaldehyde toxicity that there was no cat death in 0.46 mg/l air inhalation of acetaldehyde for 4 1/4 hr, and observed lachrymation, salivation, and disturbance in the nasal cavity, pharynx, and larynx during inhalation but he used only one cat. Kruysse (1975) reported that in a Syrian hamster, acetaldehyde LC 50 was 17,000 ppm (31,000 mg/m 3 ) × 4 hr. Skog (1950) reported that rat acetaldehyde LC 50 was 20,000 ppm (37,000 mg/m 3 ) × 0.5 hr. Appleman et al. (1982) reported that rat acetaldehyde LC 50 was 13,300 ppm (24,000 mg/m 3 ) × 4 hr. Studies have not been conducted on acetaldehyde acute inhalation in mice. However, the rat acetaldehyde LD 50 by ip injection (0.64 g/kg-body weight; Skog, 1950) and mouse acetaldehyde LD 50 by ip injection (500 mg/ kg-body weight; Truitt and Walsh, 1971 ) are approximately the same. Thus, mice acetaldehyde LC 50 was estimated to be more than 12,500 ppm, and we chose 5000 ppm for the study.
In this study, to evaluate the differences in acute inhalation toxicity of acetaldehyde, a paired acute toxicity test was performed and blood acetaldehyde levels were analyzed in the Aldh2+/+ and Aldh2−/− mice. A closed chamber without air exchange but with an air mixing fan was used because regular inhalation chambers are expensive; moreover, constant acetaldehyde concentration is not necessary to compare a pair of mice in the same chamber.
MATERIALS AND METHODS

Drugs
Acetaldehyde (SUPELCO, Bellefonte, PA) with 99.9% purity was used.
Animals
The C57BL/6J Aldh2 tm1kaw /Aldh2 tm1kaw (Aldh2−/ −) mice (Kitagawa et al., 2000; Isse et al., 2002) were maintained with a C57BL/6J strain. These were backcrossed with the C57BL/6J strain for more than 10 generations for the experiments at the animal center of the University of Occupational and Environmental Health (UOEH). The C57BL/6J strain (Charles River Japan, Yokohama, Japan) was used as the backcross strain. The littermates of male wild-type heterozygote (Aldh2+/+) and Aldh2−/− mice from heterozygote parents were set up. The animal house was maintained at 24°C (± 2°C), 55% (± 10%) humidity, and a 12-hr dark-light cycle. The room air was changed approximately 13−15 times/hr and a specific pathogen-free condition was maintained. Normal rodent chow (CRF1, Oriental Yeast Industry, Japan) was used. The animal cages and floor beds for rodent chow were used after autoclaving. The animal cages were replaced twice every week. The animal room was cleaned every day. All the animals were treated in accordance with the guidelines of the Animal Welfare and Ethics Committee of the Animal Care and Experimentation of the UOEH.
Experimental design of paired acute inhalation test
The paired acute inhalation test was performed using a 13,320 mL volume chamber and magnetic fan (M-66, Yamato, Tokyo, Japan) to stir the air inside the chamber (Fig. 1) . The air speed inside the chamber was 25 cm/s (60 s average) as measured by a thermal anemometer (ISA-80; Shibata, Tokyo, Japan). Acetaldehyde was injected using a cooled 0.5 mL gas-tight microinjector. Paired animals were put inside the chamber, and the magnetic fan was started. Thereafter, acetaldehyde was injected from the slit of the chamber lid and the slit was closed immediately. The boiling point of acetaldehyde is 21°C; therefore, the applied acetaldehyde vaporized soon after the injection and the vapors were diffused in the chamber by the magnetic fan. The animals were identified by ear punch hole and/or marking made using a black permanent marker pen. We observed the animals for 4 hr after the inhalation. After the inhalation, the surviving pair of animals was scarified for measuring the blood acetaldehyde concentration. The same experiment was repeated on five pairs of animals to determine the toxicity class.
Observation of animal symptoms in the paired acute inhalation test
We observed the general condition of the animals and recorded their mortality status (as yes/no) at the following time intervals: before the administration, at 0−5 min (JST), 5−20 min (20), 20−40 min (40), 40−60 min (1 hr), 60−120 min (2 hr), 120−180 min (3 hr), and 180−240 min (4 hr). The time periods were decided from the general conditions and symptoms were according to the National Institute of Health Science (1999) and The Japanese Society of Toxicology (2003) . The symptoms of the mice were recorded by two independent investigators. Pale skin and flushing were determined by comparing the ear, nose, foot and tail skin color of the test mice with those of non-test mice. Prone position and crouching were identified by the posture. Coma was detected by posture and pain reflex. Abnormal deep respiration, bradypnea, and dyspnea were determined by the number of chest and abdomen movements. Piloerection was detected by observing the erection of nose hair.
Measurement of blood acetaldehyde concentration
Blood was immediately collected from the decapitated trunk into liquid nitrogen-cooled plastic The chamber was made of glass and was airtight. The volume of the covered chamber was 13,320 mL, which contains sufficient air for 8 hr respiration. Liquid acetaldehyde was injected into the slit of the chamber and the slit was closed immediately after injection. Boiling point of acetaldehyde is 21°C and acetaldehyde was vaporized within a few seconds. Magnetic fan was at the bottom of the chamber, and it continuously stirred the air inside the chamber. The fan was moved by the magnetic stirrer.
tubes . The iced blood was transferred into ice cold 0.6 N perchloric acid solution (PCA) and centrifuged. Sputum sample (0.5 mL) was collected and transferred to gas-tight vials with caps for analysis. Acetaldehyde concentration was measured according to a previously described procedure (Isse et al., 2002) using a Hewlett-Packard headspace sampler (HP7694; Wilmington, DE), Hewlett-Packard gas chromatograph (HP6890, Wilmington, DE) connected to a mass spectrometer (JOEL JMS-BU20, Tokyo, Japan), and a 60 m × 0.25 mm inner diameter AQUATIC capillary column (GL Sciences, Tokyo, Japan) with a film thickness of 1.0 µm. The split ratio of the carrier gas (helium) was set to 20:1 and mass spectrometry analysis was carried out by electron impact ionization at 300 eV. The mass spectrum of acetaldehyde displayed major ions at m/z 44, 43, and 29. Acetaldehyde was determined by a selected ion monitoring method at m/z 43 and 29. The detection limit for acetaldehyde was determined by S/N = 2.5, and the quantization limit was determined by S/N = 6.0. The blood acetaldehyde levels between the Aldh2+/+ and Aldh2−/− mice were compared by using paired t-test. Statistical significance was set at p < 0.05.
RESULTS
General observations of symptoms in the paired acute inhalation test
One Aldh2−/− mouse died during the inhalation (3 h after the start of the inhalation). However, the Aldh2+/+ mice were never reported as dead in any of the cases. At the beginning of the inhalation, there was no difference in the symptoms observed in both the Aldh2+/+ and Aldh2−/− mice. Hypoactivity, incitation, and closing of eyes were observed immediately after the inhalation. A difference was observed in the symptoms 20 min after the start of inhalation. Hypoactivity, crouching, bradypnea, closed eyes, flushing, and piloerection were the symptoms observed in the Aldh2+/+ mice. The Aldh2+/+ mice did not show any signs of loss of consciousness and ataxia, and the observed symptoms were stable and/or slightly milder at the end of the inhalation as compared with those at 2 hr after the start of the inhalation. In contrast, all the Aldh2−/− mice showed severe symptoms as compared with the Aldh2+/+ mice. All the Aldh2−/− mice showed loss of consciousness and ataxia symptoms, such as prone position and straggling gait, and these symptoms became more severe in a time-dependent manner. The Aldh2−/− mice showed tearing, and the frequent incitation resulted in the formation of a white pseudo membrane on the eyes and the respiration rate 2 hr after inhalation was almost half of that of the Aldh2+/+ mice. The typical differences in symptoms are shown in Table 1 .
Blood acetaldehyde concentration
The blood acetaldehyde concentration was measured 4 hr after acetaldehyde inhalation. The Aldh2+/+ and Aldh2−/− mice showed blood acetaldehyde concentrations of 80.0 to 226.7 µM and 177.4 to 478.4 µM, respectively. The Aldh2−/− mice showed significantly higher blood acetaldehyde levels than the paired Aldh2+/+ mice ( Table 2) . 
DISUCUSSION
A difference was not found between human and mice ALDH2 tissue distributions. Human and mice tissue distributions of ALDH2 are similar in liver, lung, heart, kidney, testis, esophagus, stomach, colon, and pancreas . Cheung et al. (1999 and also reported that ALDH1, ALDH2, and ALDH3 proteins were expressed in mouse and human skin. Rat nasal mucosal homogenates oxidize acetaldehyde (Casanova-Schmitz et al., 1984) . Bogdanffy et al. (1986) identified ALDH localization in the respiratory tract of the rat. ALDH2 is distributed ubiquitously, but the liver has the highest activity and amounts of ALDH2 in the body . The homogeneity ALDH tissue distribution between human and rodent suggests the extrapolation possibility of acetaldehyde acute inhalation from rodent to human.
Respiratory uptake of acetaldehyde in humans and rodent were measured, but there were no reports on internal acetaldehyde concentrations caused by respiratory or whole body exposure. Respiratory gas analysis of human volunteers exposed to an acetaldehyde concentration below 1 ppm showed a respiratory uptake of approximately 60% (Egle, 1970) . Morris (1977) reported that the efficiency of upper respiratory tract uptake of acetaldehyde averaged 43% and 27% in mouse at inspired concentrations of 10 and 1000 ppm, respectively, using acetaldehyde vapor concentration analysis of upper respiratory tracts isolated in urethane-anesthetized animals via insertion of a polyethylene cannula. Stanek and Morris (1999) reported that the efficiency of nasal uptake of acetaldehyde in rats averaged 54%, 37%, and 34% at 10, 300, and 1500 ppm, respectively. Stanek and Morris (1999) also reported the possibility of internal exposure to acetaldehyde by inhalation in cyanamide-pretreated rats; uptake efficiencies averaged 30%, 27%, and 31% at inspired concentrations of 10, 300, and 1500 ppm, respectively. These data demonstrate the difference of acetaldehyde uptake between ALDH2-active and ALDH2-inactive individuals, and suggest that blood acetaldehyde level in blood might be increased higher in ALDH2-inactive than ALDH2-active individuals by inhalation. The present study is the first to demonstrate acetaldehyde internal exposure by inhalation.
The nasal mucosa, respiratory epithelium, and skin metabolize a part of acetaldehyde. Excess acetaldehyde is absorbed and transported to the other areas of the body by blood and is mainly metabolized in the liver. Inhalation could be assumed as a repeat exposure when the gas and/or vapor elimination rate is lower than the absorption rate (Gehring et al., 1976) . In mice, acetaldehyde was absorbed after each respiration and/ or blood circulation. The blood acetaldehyde concentration reached a plateau level, indicating that absorption and elimination had reached a steady state. In this study, we did not measure the blood acetaldehyde levels in terms of the time-course. It was unknown whether the blood acetaldehyde level in each mouse had reached the plateau level or not. However, it was clear that the blood acetaldehyde level was different because of ALDH2 activity difference. The blood acetaldehyde level recorded after ethanol gavages and ip injection supports this hypothesis. Ethanol consumption leads to continuous acetaldehyde production in the liver and is considered to be a repeat administration of acetaldehyde. The blood acetaldehyde level was signif- icantly and remarkably higher in the Aldh2−/− mice than in the Aldh2+/+ mice after ethanol gavages (Isse et al., in press ). On the other hand, during the initial periods after the administration of one shot of ip injection of acetaldehyde, the blood acetaldehyde levels in the Aldh2+/+ and Aldh2−/− mice were almost the same, although the lasting blood acetaldehyde levels were higher in the Aldh2−/− mice than in the Aldh2+/+ mice. The toxic symptoms due to acetaldehyde lasted for a longer period of time in the Aldh2−/− mice as compared with the Aldh2+/+ mice .
The major finding of this study, which was obtained by paired acute inhalation of acetaldehyde, was that the toxic symptoms were more severe in the Aldh2−/− mice than in the Aldh2+/+ mice. The blood acetaldehyde level of the Aldh2−/− mice was approximately twice that of the Aldh2+/+ mice. The blood acetaldehyde level of the Aldh2−/− mice was significantly higher than that of the Aldh2+/+ mice in all the experiments, but there was great variability among these experiments. This variability was thought to be mainly due to the variability of the acetaldehyde charge in the chamber. In this study, acetaldehyde was charged only at the beginning of the experiments, and the acetaldehyde concentrations decreased due to its clearance by absorption and metabolism in mice. We charged liquid acetaldehyde using a microinjection syringe and needle through the slit of the chamber. Immediately after the charge, we closed the slit and started the fan. Small amounts of acetaldehyde leaked during charging, and this might have caused the variability in the initial acetaldehyde concentration. Among the experiments performed, there were only small differences in body weight, activity, respiration, circulation, and the initial concentration of acetaldehyde in the chamber. These differences gave rise to the variability in absorption and metabolism of acetaldehyde and we observed the difference of blood acetaldehyde level which was thought to be due to the cumulative difference of the acetaldehyde clearance rate.
The acetaldehyde level of the Aldh2+/+ mouse in experiment number 3 is higher than the that of Aldh2−/− Test procedure of gas inhalation by the acute toxic class method with five animals each of either sex with a starting dose of 5000 ppm. Numbers in circles refer to moribund/dead animals. Vol. 30 No. 4 mouse in experiment numbers 4 and 5 (Table 2) . However, the symptoms of the Aldh2+/+ mouse in experiment number 3 was also described as Table 1 and did not show symptoms like the Aldh2−/− mouse in experiment numbers 4 and 5. The blood acetaldehyde levels were only measured at the end of the inhalation, and were not evaluated during the symptom observed. The reason for this discrepancy was thought to be due to the toxic symptom mechanism of acetaldehyde. The difference of acetaldehyde toxic symptom might be affected not mainly by the acetaldehyde level but by the acetaldehyde AUC. There are no contradictions in the relationship between blood acetaldehyde levels and the severity of the symptoms caused by acetaldehyde. Although it was difficult to quantify the severity of the symptoms, the pair of mice (Table 2 ) with the highest blood acetaldehyde concentration showed more severe bradypnea than the pair with the lowest concentration of blood acetaldehyde because the observed respiration rate was lower.
Following the LC 50 data of Skog (1950) and Appleman et al. (1982) , acetaldehyde inhalation is under the unclassified category (∞) in the acute toxicity hazard categories of the Globally Harmonized System of Classification and Labeling of Chemicals (GHS) (Fig. 2) . In this study, one of five Aldh2−/− mice died and all of them showed severe symptoms during the experiment, although none of the Aldh2+/+ mice showed any fatal symptoms. This indicates that the acetaldehyde LC 50 is over 5000 ppm in the case of Aldh2+/+ mice and that acetaldehyde inhalation is classified in the unclassified category (∞). However, the results indicate that acetaldehyde LC 50 is 5000 ppm in the case of Aldh2−/− mice and that acetaldehyde inhalation is classified category 5. In this study, the gas concentration was not strictly controlled but only set at 5000 ppm at the beginning and the concentrations decreased as time elapsed. Thus, the acetaldehyde LC 50 and GHS might fall in a more severe category if the strictly fixed concentration method is performed.
The acetaldehyde inhalation toxicity difference due to ALDH2-active/inactive individual might appear more severe in humans than mice due to the breathing. The mouse takes nasal breathing and its nose epithelium has higher ALDH2 activity than the lower respiratory tract. Some human populations take mouth breathing. In mouth breathing, the air pathway only includes the lower ALDH2 activity in contrast to nose breathing. Mouth breathing might absorb a higher amount of acetaldehyde than nose breathing and might increase the inner body acetaldehyde exposure.
The GHS has been recently adopted by the Organization for Economic Co-operation and Development (OECD). It contains harmonized classification criteria and hazard communication elements mainly for the chemical industry and transport workers. There are no consensuses as yet regarding how to treat toxicity differences among genetic polymorphisms in the GHS. The chemical toxicity differences due to genetic polymorphisms are of greater importance to protect people from chemical hazards.
For assessment of human health risk, genetic polymorphism data are conventionally not incorporated. An inter-individual variability factor of 10-fold is incorporated to account for the uncertainty created by a wide array of factors such as age, gender, nutrition and disease status, exposure to drugs, and polymorphism. This uncertainty factor can be considered as one-half log (i.e., 3.2-fold) due to pharmacokinetic variability (Renwick, 1998) . The ALDH2 polymorphism might exceed this 10-fold safety factor. Blood acetaldehyde was more than 10-fold in ALDH2 polymorphisms due to ethanol consumption in humans (19.3-fold higher; Mizoi et al., 1994) and in mice (25.2-fold higher; . However, the acetaldehyde LD 50 was not significantly different and blood acetaldehyde appeared at the same level in the ip injection study . These results imply the importance of the exposure route and scenario in pharmacokinetic and toxicokinetic studies on genetic polymorphisms. This study suggests that the paired acute inhalation test is suitable for screening the difference in toxicity caused by genetic polymorphisms prior to short-and long-term exposure studies. Further studies involving lower concentrations and long-term exposure are required to perform the risk assessment.
